➡️With the development of retzatapopt, combination therapies should be explored for those with MBC & TP53 Y220C alterations
#bcsm
@ncasasanta.bsky.socialNicole Casasanta, MD
@ncasasanta.bsky.social
Breast Medical Oncologist @YaleCancer interested in clinical/translational research
@ncasasanta.bsky.social@ncasasanta.bsky.social🔹Additional alterations more frequent in those with TP53 alterations (Y220C and non-Y220C) versus TP53wt cases included BRCA1, ERBB2, PTEN, RB1, AKT2, KRAS, MTAP, NTRK1, and VEGFA.
@ncasasanta.bsky.social🔹TP53 non-Y220C mutants had a higher frequency of TMB ≥ 10 mut/Mb vs TP53wt (8.1% vs 5.5%, p<.0001) and TMB ≥ 20 mut/Mb (2.4% vs 1.7%, p<.0001)
@ncasasanta.bsky.social🔹53% of pts w/ MBC had any TP53 alteration of which 2% were TP53 Y220C 🔹Among 217 pts with TP53 Y220C, 56.2% had TNBC, 30.4% HR+, 13.4% HER2+
@ncasasanta.bsky.social📌Excited to share our publication evaluating TP53 alterations with a closer look at TP53 Y220C alteration in metastatic breast cancer @jco-asco.bsky.social
ascopubs.org/doi/10.1200/...
@maryamlustberg.bsky.social @adrianakahn.bsky.social @yalecancer.bsky.social
